Core Viewpoint - Bristol Myers Squibb has projected its 2026 results to exceed Wall Street estimates, attributing this positive outlook to anticipated revenue growth driven by price reductions for its blood thinner, Eliquis [1] Group 1 - The company forecasts that the price cuts for Eliquis will contribute to an increase in revenue [1]